PCM
CDLX icon

Palisade Capital Management’s Cardlytics CDLX Stock Holding History

Palisade Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,032
Closed -$33K – 370
2024
Q3 		$33K Sell
1,032
-16
-2% -$888 ﹤0.01% 368
2024
Q2 		$86K Buy
+1,048
New +$113K ﹤0.01% 364

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Palisade Capital Management's CDLX Position: Q4 2024 in Review

Palisade Capital Management sold out of Cardlytics (CDLX) in Q4 2024, closing a stake of 1,032 shares — an estimated $33K sold.

Palisade Capital Management first reported a position in CDLX in Q2 2024 and held it in 2 quarters. The position peaked at $86K in Q2 2024. 108 funds tracked by Wall St. Rank hold CDLX as of Q4 2024.

  • Palisade Capital Management reported no remaining Cardlytics position as of Q4 2024 after selling out during the quarter.
  • Palisade Capital Management sold 1,032 Cardlytics shares in Q4 2024, an estimated $33K.
  • Palisade Capital Management first reported a position in Cardlytics in Q2 2024 and held it in 2 quarters.
  • Palisade Capital Management's Cardlytics position peaked at $86K in Q2 2024.
  • 108 funds tracked by Wall St. Rank held Cardlytics as of Q4 2024.

Based on Palisade Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.